Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib versus Erlotinib as First-line Treatment of EGFR-Mutated NSCLC at Chaophrayayommarat Hospital
TCTR20231002008Unknown
- Sponsor
- Chaoprayayommarat Hospital Research Ethical Committee
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of gefitinib and erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chaoprayayommarat Hospital Research Ethical Committee. Primary endpoint: overall_survival. Status: unknown.
02
Drugs
gefitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on TCTR20231002008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20231002008.